Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen's denosumab becomes first drug to delay bone metastases in cancer

This article was originally published in Scrip

Executive Summary

Amgen's novel drug Xgeva (denosumab) has become the first agent which has been shown in a large trial to delay the development of bone metastases in cancer, after meeting its primary endpoint in a long-awaited Phase III trial in prostate cancer. Amgen revealed top-line data of the study, which showed that denosumab improved median bone metastases-free survival by a median of about four months.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts